Back to Search Start Over

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

Authors :
Universidad de Sevilla. Departamento de Medicina
"Una manera de hacer Europa" (Innocampus) CEI-2010-1-0010
Celgene grant
CRIS against Cancer foundation 2018/001
Fundacion Espanola de Hematologia y Hemoterapia
Instituto de Investigacion Sanitaria La Fe 2019-052-1
Instituto de Salud Carlos III PI15/01706; PI16/00517; PI16/0665; PI16/01530; PI18/01340; PI18/01946; PI19/00730; PI19/01518; FI19/00059
Sargas, Claudia
Ayala, Rosa
Chillón, María del Carmen
Larráyoz, María J.
Carrillo-Cruz, Estrella
Bilbao, Cristina
Pérez Simón, José Antonio
Montesinos, Pau
Universidad de Sevilla. Departamento de Medicina
"Una manera de hacer Europa" (Innocampus) CEI-2010-1-0010
Celgene grant
CRIS against Cancer foundation 2018/001
Fundacion Espanola de Hematologia y Hemoterapia
Instituto de Investigacion Sanitaria La Fe 2019-052-1
Instituto de Salud Carlos III PI15/01706; PI16/00517; PI16/0665; PI16/01530; PI18/01340; PI18/01946; PI19/00730; PI19/01518; FI19/00059
Sargas, Claudia
Ayala, Rosa
Chillón, María del Carmen
Larráyoz, María J.
Carrillo-Cruz, Estrella
Bilbao, Cristina
Pérez Simón, José Antonio
Montesinos, Pau
Publication Year :
2021

Abstract

Next-generation sequencing (NGS) has recently been introduced to efficiently and simultaneously detect genetic variations in acute myeloid leukemia (AML). However, its implementation in the clinical routine raises new challenges focused on the diversity of assays and variant reporting criteria. In order to overcome this challenge, the PETHEMA group established a nationwide network of reference laboratories aimed to deliver molecular results in the clinics. We report the technical cross-validation results for NGS panel genes during the standardization process and the clinical validation in 823 samples of 751 patients with newly diagnosed or refractory/relapse AML. Two cross-validation rounds were performed in seven nationwide reference laboratories in order to reach a consensus regarding quality metrics criteria and variant reporting. In the pre-standardization cross-validation round, an overall concordance of 60.98% was obtained with a great variability in selected genes and conditions across laboratories. After consensus of relevant genes and optimization of quality parameters the overall concordance rose to 85.57% in the second cross-validation round. We show that a diagnostic network with harmonized NGS analysis and reporting in seven experienced laboratories is feasible in the context of a scientific group. This cooperative nationwide strategy provides advanced molecular diagnostic for AML patients of the PETHEMA group (clinicaltrials gov. Identifier: NCT03311815).

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1367054683
Document Type :
Electronic Resource